Your browser doesn't support javascript.
loading
Combination of Small Extracellular Vesicle-Derived Annexin A2 Protein and mRNA as a Potential Predictive Biomarker for Chemotherapy Responsiveness in Aggressive Triple-Negative Breast Cancer.
Desai, Priyanka P; Narra, Kalyani; James, Johanna D; Jones, Harlan P; Tripathi, Amit K; Vishwanatha, Jamboor K.
Afiliación
  • Desai PP; Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, Texas, TX 76107, USA.
  • Narra K; Department of Internal Medicine, John Peter Smith (JPS) Oncology Infusion Center, Fort Worth, Texas, TX 76104, USA.
  • James JD; Biosample Repository Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
  • Jones HP; Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, Texas, TX 76107, USA.
  • Tripathi AK; Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, Texas, TX 76107, USA.
  • Vishwanatha JK; Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, Texas, TX 76107, USA.
Cancers (Basel) ; 15(1)2022 Dec 29.
Article en En | MEDLINE | ID: mdl-36612209
Small extracellular vesicles (sEVs), mainly exosomes, are nanovesicles that shed from the membrane as intraluminal vesicles of the multivesicular bodies, serve as vehicles that carry cargo influential in modulating the tumor microenvironment for the multi-step process of cancer metastasis. Annexin A2 (AnxA2), a calcium(Ca2+)-dependent phospholipid-binding protein, is among sEV cargoes. sEV-derived AnxA2 (sEV-AnxA2) protein is involved in the process of metastasis in triple-negative breast cancer (TNBC). The objective of the current study is to determine whether sEV-AnxA2 protein and/or mRNA could be a useful biomarkers to predict the responsiveness of chemotherapy in TNBC. Removal of Immunoglobulin G (IgG) from the serum as well as using the System Bioscience's ExoQuick Ultra kit resulted in efficient sEV isolation and detection of sEV-AnxA2 protein and mRNA compared to the ultracentrifugation method. The standardized method was applied to the twenty TNBC patient sera for sEV isolation. High levels of sEV-AnxA2 protein and/or mRNA were associated with stage 3 and above in TNBC. Four patients who responded to neoadjuvant chemotherapy had high expression of AnxA2 protein and/or mRNA in sEVs, while other four who did not respond to chemotherapy had low levels of AnxA2 protein and mRNA in sEVs. Our data suggest that the sEV-AnxA2 protein and mRNA could be a combined predictive biomarker for responsiveness to chemotherapy in aggressive TNBC.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza